AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
25 juin 2024 08h00 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic...
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
25 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Afamelanotide in fair-skinned Parkinson’s patients
17 juin 2024 20h39 HE
|
Clinuvel Pharmaceuticals Limited
CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
28 mai 2024 07h00 HE
|
NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
30 avr. 2024 08h00 HE
|
Alumis Inc
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17 avr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
Parkinson’s Disease Increasing In U.S., Highlighting Importance Of SSDI Benefits, Allsup Explains
16 avr. 2024 12h32 HE
|
Allsup
Belleville, Illinois, April 16, 2024 (GLOBE NEWSWIRE) -- The number of Americans with Parkinson’s disease (PD) continues to increase, highlighting the importance of financial supports for...
RaceTrac Adds Java Jolt to Parkinson’s Research Funding and Awareness with 13th Annual ‘Coffee For A Cause’ Week
27 mars 2024 13h31 HE
|
Racetrac, Inc.
Atlanta, March 27, 2024 (GLOBE NEWSWIRE) -- In recognition of Parkinson’s Awareness Month, RaceTrac is once again proud to partner with The Michael J. Fox Foundation (MJFF) by offering ‘Coffee For A...
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
14 mars 2024 07h57 HE
|
ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
11 mars 2024 08h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients